HealthDay on MSN1mon
FDA Approves Emrosi for Rosacea in AdultsTUESDAY, Nov. 12, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Emrosi (minocycline ...
Medpage Today on MSN1mon
FDA Approves New Option for RosaceaThe FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in ...
The US’ Food and Drug Administration (FDA ... Emrosi, the brand name for its 40mg minocycline hydrochloride extended-release capsules, to be used in the treatment of dermatological condition ...
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder. The new capsule formulation of the ...
The US Food and Drug Administration (FDA) has approved ustekinumab-kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque ...
The FDA has approved Rapiblyk, a new drug to treat irregular heartbeats in critically ill hospitalized patients with severe supraventricular tachycardia (SVT), including atrial fibrillation and ...
Acoramidis is the first FDA-approved treatment for ATTR-CM with near-complete TTR stabilization, reducing cardiovascular death and hospitalization. The phase 3 ATTRibute-CM trial showed acoramidis ...
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation. The Food and Drug Administration (FDA) approved Revuforj (revumenib) for ...
The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of inflammatory rosacea in adults. The extended-release capsules (40 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results